Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
Rattachement africain : sa, cn, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND AND AIMS: Combining probiotics and prebiotics in synbiotics may present a synergistic approach to improve type 2 diabetes mellitus (T2DM); however, further evidence is required to establish the comparative efficacy of synbiotics versus probiotics. This study aimed to evaluate the effects of Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) and a synbiotic mixture of MN-Gup and galactooligosaccharide (MN-Gup-GOS) on glycemic control in T2DM patients and explore possible mechanisms. METHODS: This randomized, double-blind, placebo-controlled clinical trial assigned 120 T2DM patients, to receive MN-Gup, MN-Gup-GOS, or placebo intervention for 12 weeks. The primary outcome was fasting blood glucose (FBG), with secondary outcomes including hemoglobin A1C (HbA1C), insulin, homeostatic model assessment of insulin resistance (HOMA-IR), inflammatory indicators, oxidative stress indicators, gastrointestinal hormones, gut microbiota, and bile acids (BAs). RESULTS: The median age of the 120 participants was 59 years (interquartile range: 55-62 years), with 40 being men. Compared to baseline, all three groups exhibited significant reductions in FBG. Additionally, the MN-Gup-GOS group demonstrated significant decreases in HbA1c, serum insulin, and HOMA-IR after intervention, whereas no such reductions were observed in the placebo and MN-Gup groups. Regarding the between-group comparisons, the MN-Gup-GOS intervention showed a significantly greater reduction in FBG compared to the placebo (least squares mean difference [95 % CI], -0.69 [-1.29, -0.10] mmol/L, P = 0.022) and MN-Gup (-0.59 [-1.17, -0.01], P = 0.047) group, but not for other indicators of glucose metabolism. Additionally, MN-Gup and MN-Gup-GOS intervention, especially the latter, significantly modified inflammation, oxidative stress, gut microbiota, serum BAs, and GLP-1 levels. Correlation analysis showed significant associations between changes in certain gut microbiota (Bifidobacterium) and BAs (deoxycholic acid and lithocholic acid) with glycemic indicators. CONCLUSIONS: The auxiliary effect of synbiotics MN-Gup-GOS on reducing FBG levels surpassed that of MN-Gup probiotics alone in T2DM patients, potentially attributed to the enhanced modulation of gut microbiota, BAs, and GLP-1 secretion. TRIAL REGISTRATION: This study was registered on the website of www.chictr.org.cn, number ChiCTR2100052187.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effects of synbiotics surpass probiotics alone in improving type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial
- Date Crossref
- 01/01/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Ministry of Education pays non établi dans la noticeOrganisme public
-
Chinese PLA General Hospital pays non établi dans la noticeÉtablissement de santé
-
First Affiliated Hospital of Chinese PLA General Hospital pays non établi dans la noticeÉtablissement de santé
-
Columbia University Department of Obstetrics and Gynecology pays non établi dans la noticeUniversité ou école supérieure
-
China Agricultural University Department of Nutrition and Health pays non établi dans la noticeUniversité ou école supérieure
-
Henan University of Science and Technology pays non établi dans la noticeUniversité ou école supérieure
-
Tiandi Science & Technology (China) pays non établi dans la noticeEntreprise
-
Fudan University Greater Bay Area Institute of Precision Medicine (Guangzhou) pays non établi dans la noticeUniversité ou école supérieure
-
Greater Bay Area Institute of Precision Medicine pays non établi dans la noticeOrganisme public
-
Jingdong (China) pays non établi dans la noticeEntreprise
-
Ltd. Mengniu Hi-Tech Dairy Product Beijing Co. pays non établi dans la noticeEntreprise
-
The first medical Center of PLA General Hospital Department of Nutrition pays non établi dans la noticeÉtablissement de santé
Ministry of Education, Chinese PLA General Hospital et First Affiliated Hospital of Chinese PLA General Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.